The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP -1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP -1 receptor agonists
However, they have also become increasingly popular for weight loss due to their ability to slow digestion and reduce appetite
This represents an abnormal processing of sensory information by the nervous system
*Correspondence: Niklas Reich, [email protected] This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Pancreatitis : Individuals with a history of pancreatitis should avoid semaglutide or use it cautiously
While missing one weekly dose of a GLP-1 or GIP/GLP-1 receptor agonist is generally not medically dangerous, prolonged interruption can lead to return of appetite, potential weight regain, and in patients with type 2 diabetes, deterioration of glycemic control